51. Faecal microbiota transplantation in endocrine diseases and obesity
- Author
-
Coco M. Fuhri Snethlage, Nordin M J Hanssen, and Max Nieuwdorp
- Subjects
0301 basic medicine ,endocrine system ,endocrine system diseases ,type 1 diabetes ,Endocrinology, Diabetes and Metabolism ,faecal microbiota transplant ,microbiome ,030209 endocrinology & metabolism ,Type 2 diabetes ,Bioinformatics ,Faecal microbiota transplantation ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,medicine ,Humans ,Endocrine system ,Obesity ,Microbiome ,Type 1 diabetes ,business.industry ,nutritional and metabolic diseases ,Type 2 Diabetes Mellitus ,Fecal Microbiota Transplantation ,medicine.disease ,Gut microbiome ,Gastrointestinal Microbiome ,030104 developmental biology ,Diabetes Mellitus, Type 2 ,type 2 diabetes ,Insulin Resistance ,business - Abstract
The prevalence of type 1 (T1D) and type 2 diabetes mellitus (T2D) has greatly increased worldwide over the last century. Although the exact pathophysiology of both these conditions is distinct and still largely unknown, T1D as well as T2D, have been linked to distinct perturbations of the gut microbiome. Faecal microbiota transplantation (FMT) is a potent, and if performed well, a safe method to modulate the composition of the gut microbiome and thus positively influences the course of these hyperglycaemic conditions in humans. In this review, we provide an overview of how FMT is commonly performed and summarise how this procedure may reduce the insulin-resistance driving T2D, and the underlying auto-immunity driving T1D. Insights derived from FMT studies in T1D and T2D may help identify beneficial microbiota and associated metabolites that may serve as future treatments for these conditions.
- Published
- 2021